U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H21N5O5S
Molecular Weight 491.519
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NEBENTAN

SMILES

COC1=CC=CC=C1OC2=C(OC)N=C(N=C2NS(=O)(=O)\C=C\C3=CC=CC=C3)C4=NC=CC=N4

InChI

InChIKey=LONWRQOYFPYMQD-DTQAZKPQSA-N
InChI=1S/C24H21N5O5S/c1-32-18-11-6-7-12-19(18)34-20-21(29-35(30,31)16-13-17-9-4-3-5-10-17)27-23(28-24(20)33-2)22-25-14-8-15-26-22/h3-16H,1-2H3,(H,27,28,29)/b16-13+

HIDE SMILES / InChI

Molecular Formula C24H21N5O5S
Molecular Weight 491.519
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Nebentan (YM598) is an orally active synthetic substituted phenylethenesulfonamide. As a selective endothelin A receptor antagonist, YM598 inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis. The inhibitory dissociation constant value of YM598 was 0.772 nM for native human ETA receptors, and 143 nM for native human ETB subtypes. The calculated selectivity ratio of YM598 for ETA versus ETB receptors was 222. In pithed rats, YM598 inhibited the big endothelin-1 (1 nmol/kg)-induced pressor response in a dose-dependent manner, after both intravenous and oral administration. YM598 showed not only superior antagonistic activity and higher-selectivity for endothelin ET(A) receptor in vitro, but at least a 30-fold higher potency in vivo than bosentan.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist.
2003 Sep 30
Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats.
2004 Feb
In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract.
2008 Feb 12
Patents

Sample Use Guides

In the in vivo study, endothelin-1 induced the elevation of non-prostatic urethral pressure as well as prostatic urethral pressure even in the presence of tamsulosin (10 microg/kg, i.v.) in anesthetized male dogs. Nebentan (0.1-3 mg/kg, i.v.) inhibited these endothelin-1-induced contractile responses in a dose-dependent fashion.
Route of Administration: Intravenous
In the in vitro study, endothelin-1 induced contractile responses in isolated rabbit bladder base, urethra, and prostate tissues. Nebentan (10(-7)-10(-5) M) antagonized endothelin-1-induced contractile responses without affecting the maximal responses. YM598 inhibited [125I]endothelin-1 binding to cloned human endothelin ET(A) and ET(B) receptor, with K(i) of 0.697 and 569 nM, and inhibited endothelin-1-induced increases in intracellular Ca(2+) concentration in human and rat endothelin ET(A) receptor. YM598 also inhibited endothelin-1-induced vasoconstriction in isolated rat aorta with a pA(2) value of 7.6.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:03:17 UTC 2023
Edited
by admin
on Sat Dec 16 18:03:17 UTC 2023
Record UNII
IJ670B0H4A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NEBENTAN
INN  
INN  
Official Name English
nebentan [INN]
Common Name English
(E)-N-(6-METHOXY-5-(2-METHOXYPHENOXY)-2,2'-BIPYRIMIDIN-4-YL)-2-PHENYLETHENESULFONAMIDE
Systematic Name English
HE-11
Code English
Code System Code Type Description
NCI_THESAURUS
C81108
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
ChEMBL
CHEMBL2107760
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
PUBCHEM
9957262
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
EPA CompTox
DTXSID50193350
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
CAS
403604-85-3
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
INN
8416
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
FDA UNII
IJ670B0H4A
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
SMS_ID
100000178109
Created by admin on Sat Dec 16 18:03:17 UTC 2023 , Edited by admin on Sat Dec 16 18:03:17 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY